412 related articles for article (PubMed ID: 26832745)
1. NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
Charych DH; Hoch U; Langowski JL; Lee SR; Addepalli MK; Kirk PB; Sheng D; Liu X; Sims PW; VanderVeen LA; Ali CF; Chang TK; Konakova M; Pena RL; Kanhere RS; Kirksey YM; Ji C; Wang Y; Huang J; Sweeney TD; Kantak SS; Doberstein SK
Clin Cancer Res; 2016 Feb; 22(3):680-90. PubMed ID: 26832745
[TBL] [Abstract][Full Text] [Related]
2. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Charych D; Khalili S; Dixit V; Kirk P; Chang T; Langowski J; Rubas W; Doberstein SK; Eldon M; Hoch U; Zalevsky J
PLoS One; 2017; 12(7):e0179431. PubMed ID: 28678791
[TBL] [Abstract][Full Text] [Related]
3. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
Bentebibel SE; Hurwitz ME; Bernatchez C; Haymaker C; Hudgens CW; Kluger HM; Tetzlaff MT; Tagliaferri MA; Zalevsky J; Hoch U; Fanton C; Aung S; Hwu P; Curti BD; Tannir NM; Sznol M; Diab A
Cancer Discov; 2019 Jun; 9(6):711-721. PubMed ID: 30988166
[TBL] [Abstract][Full Text] [Related]
4. NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8
Walker JM; Rolig AS; Charych DH; Hoch U; Kasiewicz MJ; Rose DC; McNamara MJ; Hilgart-Martiszus IF; Redmond WL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457127
[TBL] [Abstract][Full Text] [Related]
5. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Sharma M; Khong H; Fa'ak F; Bentebibel SE; Janssen LME; Chesson BC; Creasy CA; Forget MA; Kahn LMS; Pazdrak B; Karki B; Hailemichael Y; Singh M; Vianden C; Vennam S; Bharadwaj U; Tweardy DJ; Haymaker C; Bernatchez C; Huang S; Rajapakshe K; Coarfa C; Hurwitz ME; Sznol M; Hwu P; Hoch U; Addepalli M; Charych DH; Zalevsky J; Diab A; Overwijk WW
Nat Commun; 2020 Jan; 11(1):661. PubMed ID: 32005826
[TBL] [Abstract][Full Text] [Related]
6. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
Hennessy M; Wahba A; Felix K; Cabrera M; Segura MG; Kundra V; Ravoori MK; Stewart J; Kleinerman ES; Jensen VB; Gopalakrishnan V; Pena R; Quach P; Kim G; Kivimäe S; Madakamutil L; Overwijk WW; Zalevsky J; Gordon N
Int J Cancer; 2021 Apr; 148(8):1928-1937. PubMed ID: 33152115
[TBL] [Abstract][Full Text] [Related]
7. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
Miyazaki T; Maiti M; Hennessy M; Chang T; Kuo P; Addepalli M; Obalapur P; Sheibani S; Wilczek J; Pena R; Quach P; Cetz J; Moffett A; Tang Y; Kirk P; Huang J; Sheng D; Zhang P; Rubas W; Madakamutil L; Kivimäe S; Zalevsky J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34001523
[TBL] [Abstract][Full Text] [Related]
8. A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy.
Hsu EJ; Cao X; Moon B; Bae J; Sun Z; Liu Z; Fu YX
Nat Commun; 2021 May; 12(1):2768. PubMed ID: 33986267
[TBL] [Abstract][Full Text] [Related]
9. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
Drerup JM; Deng Y; Pandeswara SL; Padrón ÁS; Reyes RM; Zhang X; Mendez J; Liu A; Clark CA; Chen W; Conejo-Garcia JR; Hurez V; Gupta H; Curiel TJ
Cancer Res; 2020 Nov; 80(22):5063-5075. PubMed ID: 32948605
[TBL] [Abstract][Full Text] [Related]
10. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
[TBL] [Abstract][Full Text] [Related]
11. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist.
Parisi G; Saco JD; Salazar FB; Tsoi J; Krystofinski P; Puig-Saus C; Zhang R; Zhou J; Cheung-Lau GC; Garcia AJ; Grasso CS; Tavaré R; Hu-Lieskovan S; Mackay S; Zalevsky J; Bernatchez C; Diab A; Wu AM; Comin-Anduix B; Charych D; Ribas A
Nat Commun; 2020 Jan; 11(1):660. PubMed ID: 32005809
[TBL] [Abstract][Full Text] [Related]
12. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
[TBL] [Abstract][Full Text] [Related]
13. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
14. NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells.
Robinson TO; Hegde SM; Chang A; Gangadharan A; Rivas S; Madakamutil L; Zalevsky J; Miyazaki T; Schluns KS
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34375310
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
16. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
[TBL] [Abstract][Full Text] [Related]
17. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8
Rolig AS; Rose DC; McGee GH; Rubas W; Kivimäe S; Redmond WL
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444059
[TBL] [Abstract][Full Text] [Related]
18. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
[TBL] [Abstract][Full Text] [Related]
19. Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions.
Wen Q; Xiong W; He J; Zhang S; Du X; Liu S; Wang J; Zhou M; Ma L
J Transl Med; 2016 Feb; 14():41. PubMed ID: 26850448
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
Pretto F; Elia G; Castioni N; Neri D
Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
